Skip to main content
Quest Diagnostics

Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study

Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study

Authors: Heo M, Norton BL, Pericot-Valverde I, Mehta SH, Tsui JI, Taylor LE, Lum PJ, Feinberg J, Kim AY, Arnsten J, Sprecht-Walsh S, Page K, Litwin AH; HERO Study Group; National Stakeholder Advisory Board

Citation: J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023.12.020. Online ahead of print.

Specialties: Infectious disease, Prescription drug monitoring, Toxicology

Related content

Publication
Hepatitis C virus clearance cascade — United States, 2013–2022
Publication
Hepatitis C Virus Testing During Pregnancy Following Universal Screening Recommendations
Publication
Low performance of hepatitis delta virus testing among two national cohorts of chronic hepatitis B patients in the United States
Publication
Relationship Between Hepatitis C Virus (HCV) IgG Index Values and Quantitative HCV RNA Results in HCV IgG-Reactive Serum Samples
Test FAQ
Donor Testing
Test FAQ
Drug monitoring, Phoshatidylethanol (PEth), Blood Test

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.